DUCHENNE MUSCULAR DYSTROPHY (DMD)

Duchenne is the **MOST COMMON AND SEVERE** muscular dystrophy in children.

**X-LINKED** recessive disorder, that affects mainly boys.

Caused by mutations in the **DYSTROPHIN GENE**, and the loss of dystrophin which provides structural stability to muscle cells.

Leads to **PROGRESSIVE MUSCLE WEAKNESS** and wasting. Early intervention can slow the course of the disease.¹

Affects ~1:5000 male births worldwide

Estimated 300,000 sufferers worldwide²

Symptoms appear at ~2.5 **YEARS** of age

Diagnosis as late as at ~4-5 **YEARS** of age

---

¹ For the Better

² PerkinElmer
WHY SCREEN FOR DUCHENNE IN NEWBORNS?

“Future therapeutic interventions are likely to make a real difference to prognosis only if they can be instituted early.”

Advances in new therapies:
- 3 FDA approved drugs available
- Over 70 clinical trials ongoing

Help families plan earlier:
- Finding a neuromuscular provider
- Start early therapy (stretching, and physical therapy)
- Starting corticosteroids and other disease modifying treatments
- Family planning
- Enroll in clinical trials

GSP® Neonatal Creatine Kinase –MM kit
- First FDA cleared CE-IVD assay for Duchenne Newborn Screening now available by PerkinElmer
- GSP® Neonatal Creatine Kinase –MM kit separates well DMD affected cases from normal newborns
- Over 200K babies screened worldwide using GSP® Neonatal CK –MM kit
- Based on reliable DELFIA® Immunoassay

Find out more by visiting our website: www.newbornscreening.perkinelmer.com/disorders
or by contacting your local representative

References:
2. Duchenne UK website: https://www.duchenneuk.org/Pages/FAQs/Category/what-is-duchenne
4. FDA cleared drugs for Duchenne: https://www.parentprojectmd.org/duchenne-drug-development-pipeline

Products may not be licensed in accordance with the laws in all countries, such as Canada. Please check with your local representative for availability.